The PE Ratio as of September 2024 (TTM) for Genscript Biotech Corporation (GNNSF) is -17.62

According to Genscript Biotech Corporation’s latest financial reports and current stock price. The company's current PE Ratio is -17.62. This represents a change of -96.61% compared to the average of -520.37 of the last 4 quarters.

Genscript Biotech Corporation (GNNSF) Historical PE Ratio (quarterly & annually)

How has GNNSF PE Ratio performed in the past?

The mean historical PE Ratio of Genscript Biotech Corporation over the last ten years is 47.98. The current -17.62 PE Ratio has changed -3772.35% with respect to the historical average. Over the past ten years (40 quarters), GNNSF's PE Ratio was at its highest in in the September 2018 quarter at 281.78. The PE Ratio was at its lowest in in the September 2023 quarter at -1389.47.

Genscript Biotech Corporation (GNNSF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Genscript Biotech Corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Genscript Biotech Corporation (GNNSF) Average PE Ratio

How has GNNSF PE Ratio performed in the past?

The current PE Ratio of Genscript Biotech Corporation (GNNSF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Genscript Biotech Corporation (GNNSF) PE Ratio vs. Peers

How is GNNSF’s PE Ratio compared to its peers?

Genscript Biotech Corporation’s PE Ratio is less than Telix Pharmaceuticals Limited (99.85), less than Keros Therapeutics, Inc. (-12.31), less than Zentalis Pharmaceuticals, Inc. (-1.59), greater than Innovent Biologics, Inc. (-35.05), less than Oxford Nanopore Technologies plc (0), less than Nuvalent, Inc. (-5.19), greater than Crinetics Pharmaceuticals, Inc. (-38.43), less than Inhibrx, Inc. (-16.47), less than Merus N.V. (0.15), greater than Lyell Immunopharma, Inc. (-18.74), less than Kronos Bio, Inc. (-1.89), less than AgeX Therapeutics, Inc. (-0.55), less than Lineage Cell Therapeutics, Inc. (-1.48), less than Cadrenal Therapeutics, Inc. Common Stock (-7.10), less than ImmuCell Corporation (-1.92), less than Neoleukin Therapeutics, Inc. (-7.00), less than Nuvation Bio Inc. (-0.98), less than Ovid Therapeutics Inc. (-1.41), less than NextCure, Inc. (-2.79), less than Connect Biopharma Holdings Limited (-0.65), less than null (-2.98),

Build a custom stock screener for Genscript Biotech Corporation (GNNSF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genscript Biotech Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genscript Biotech Corporation (GNNSF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genscript Biotech Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.